猫咪减肥药来了！国内宠物医疗相关企业近2万，专利超2000项

Core Insights - The role of pets has shifted from "animals" to "family members," leading to increased owner concern for pet health and a surge in high-value products such as pet pharmaceuticals, health supplements, and functional prescription foods [1] Group 1: Market Growth and Trends - The introduction of a new weight loss drug for cats, "Pralmorelin Injection," has been accepted for registration by the Ministry of Agriculture and Rural Affairs, showing an average weight loss of 9.26% in trial cats after six weeks [1] - Pet health is identified as the primary driver of consumer growth, with projected increases in pet prescription food by 290%, pet treatment drugs by 80%, and calming products by over 90% by 2025, significantly outpacing traditional categories [1] Group 2: Industry Landscape - As of January 5, there are 17,400 existing pet medical-related companies in China, with 1,909 new registrations expected in 2025, reflecting an 8.59% year-on-year growth [2][3] - The majority of existing pet medical companies (40.29%) were established 5-10 years ago, while companies established 1-3 years and 3-5 years account for 19.15% and 18.51%, respectively [3] Group 3: Regional Distribution - Pet medical-related companies are predominantly located in East China, accounting for 38.75% of the total, followed by Central China (14.66%) and South China (14.52%) [6] Group 4: Patent Landscape - There are currently 2,768 existing patents related to pet medicine in China, with over 60% being invention patents, including 53.41% for published inventions and 11.24% for authorized inventions [7] - The annual application volume for related patents has fluctuated between 140 and 260 over the past decade, with an expected total of 166 applications in 2025 [7]